Atherosclerotic Cardiovascular Disease

The Atherosclerotic Cardiovascular Disease pipeline: 116 tracked drugs, 17 approved for this indication.

17 approved / phase 441 Phase 31 Phase 2/324 Phase 24 Phase 1/219 Phase 110 preclinical / unstaged

Compare the share prices of listed companies in Atherosclerotic Cardiovascular Disease →

Total attributable cost

$69.5B

$3,494/patient

Drug spend

$22.7B

$1,139/patient

How this is calculated ↗

All severities (2015-2018 NHANES cycle) · US

The Atherosclerotic Cardiovascular Disease pipeline

Key trial results for every approved and late-stage drug: Atherosclerotic Cardiovascular Disease results by drug.

← all assets